
1. malar j. 2012 dec 12;11:416. doi: 10.1186/1475-2875-11-416.

efficacy tolerability new formulation artesunate-mefloquine the
treatment uncomplicated malaria adult senegal: open randomized trial.

tine rc(1), faye b, sylla k, ndiaye jl, ndiaye m, sow d, lo ac, abiola a, ba mc, 
gaye o.

author information: 
(1)department parasitology, faculty medicine, university cheikh anta diop, 
dakar, senegal. roger.tine@ucad.edu.sn

background: prompt treatment malaria attacks arteminisin-based
combination therapy (act) essential tool malaria control. new
co-blister tablet artesunate-mefloquine (am) 25 mg/kg mefloquine been
developed management uncomplicated malaria attacks. this
non-inferiority randomized trial, conducted evaluate efficacy and
safety new formulation comparison artemether-lumefantrine (al)
for treatment acute uncomplicated plasmodium falciparum malaria adults 
in senegal.
methods: study carried september december 2010 two health 
centres senegal. study end points included (i) pcr corrected adequate
clinical parasitological response (acpr) day 28, (ii) acpr days 42 
63, (iii) parasites fever clearance time, (iv) incidence adverse events
and patients biological profile day 7 using 2003 protocol for
anti-malarial drug evaluation.
results: overall, 310 patients randomized receive either (n = 157) 
al (n = 153). pcr corrected acpr day 28 95.5% arm 
in al arm 96.7% (p = 0.83). therapeutic efficacy 98.5% the
am arm versus 98.2% al group day 42 (p = 1). day 63, acpr 
and al arms 98.2% 97.7%, respectively (p = 0.32). two treatments
were well tolerated similar biological profile day 7. however, dizziness 
was frequent arm.
conclusion: artesunate-mefloquine (25 mg/kg mefloquine) efficacious and
well-tolerated treatment uncomplicated p. falciparum malaria adult 
patients.

doi: 10.1186/1475-2875-11-416 
pmcid: pmc3554515
pmid: 23234606  [indexed medline]

